About: Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease
Creator	Liu, Jing Hu, Yi Tao, Zhao-Wu Yuan, Ming-Li Yang, Ming Zhou, Ling Liu, Wei Wang, Lei Liu, Kui Liu, Hui-Guo Ming, Yang Yi, Hu Deng, Yan Wei, Shuang
source	Medline; PMC
abstract	BACKGROUND: Since early December 2019, the 2019 novel coronavirus disease (COVID-19) has caused pneumonia epidemic in Wuhan, Hubei province of China. This study aims to investigate the factors affecting the progression of pneumonia in COVID-19 patients. Associated results will be used to evaluate the prognosis and to find the optimal treatment regimens for COVID-19 pneumonia. METHODS: Patients tested positive for the COVID-19 based on nucleic acid detection were included in this study. Patients were admitted to 3 tertiary hospitals in Wuhan between December 30, 2019, and January 15, 2020. Individual data, laboratory indices, imaging characteristics, and clinical data were collected, and statistical analysis was performed. Based on clinical typing results, the patients were divided into a progression group or an improvement/stabilization group. Continuous variables were analyzed using independent samples t-test or Mann-Whitney U test. Categorical variables were analyzed using Chi-squared test or Fisher's exact test. Logistic regression analysis was performed to explore the risk factors for disease progression. RESULTS: Seventy-eight patients with COVID-19-induced pneumonia met the inclusion criteria and were included in this study. Efficacy evaluation at 2 weeks after hospitalization indicated that 11 patients (14.1%) had deteriorated, and 67 patients (85.9%) had improved/stabilized. The patients in the progression group were significantly older than those in the disease improvement/stabilization group (66 [51, 70] vs. 37 [32, 41] years, U = 4.932, P = 0.001). The progression group had a significantly higher proportion of patients with a history of smoking than the improvement/stabilization group (27.3% vs. 3.0%, χ(2) = 9.291, P = 0.018). For all the 78 patients, fever was the most common initial symptom, and the maximum body temperature at admission was significantly higher in the progression group than in the improvement/stabilization group (38.2 [37.8, 38.6] vs. 37.5 [37.0, 38.4]°C, U = 2.057, P = 0.027). Moreover, the proportion of patients with respiratory failure (54.5% vs. 20.9%, χ(2) = 5.611, P = 0.028) and respiratory rate (34 [18, 48] vs. 24 [16, 60] breaths/min, U = 4.030, P = 0.004) were significantly higher in the progression group than in the improvement/stabilization group. C-reactive protein was significantly elevated in the progression group compared to the improvement/stabilization group (38.9 [14.3, 64.8] vs. 10.6 [1.9, 33.1] mg/L, U = 1.315, P = 0.024). Albumin was significantly lower in the progression group than in the improvement/stabilization group (36.62 ± 6.60 vs. 41.27 ± 4.55 g/L, U = 2.843, P = 0.006). Patients in the progression group were more likely to receive high-level respiratory support than in the improvement/stabilization group (χ(2) = 16.01, P = 0.001). Multivariate logistic analysis indicated that age (odds ratio [OR], 8.546; 95% confidence interval [CI]: 1.628–44.864; P = 0.011), history of smoking (OR, 14.285; 95% CI: 1.577–25.000; P = 0.018), maximum body temperature at admission (OR, 8.999; 95% CI: 1.036–78.147, P = 0.046), respiratory failure (OR, 8.772, 95% CI: 1.942–40.000; P = 0.016), albumin (OR, 7.353, 95% CI: 1.098–50.000; P = 0.003), and C-reactive protein (OR, 10.530; 95% CI: 1.224−34.701, P = 0.028) were risk factors for disease progression. CONCLUSIONS: Several factors that led to the progression of COVID-19 pneumonia were identified, including age, history of smoking, maximum body temperature at admission, respiratory failure, albumin, C-reactive protein. These results can be used to further enhance the ability of management of COVID-19 pneumonia.
has issue date	2020-02-28(xsd:dateTime)
bibo:doi	10.1097/cm9.0000000000000775
bibo:pmid	32118640
has license	no-cc
sha1sum (hex)	1c3f83f83bc725064f9d634d10facb8ec2254bec
schema:url	https://doi.org/10.1097/cm9.0000000000000775
resource representing a document's title	Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease
has PubMed Central identifier	PMC7147279
has PubMed identifier	32118640
schema:publication	Chin Med J (Engl)
resource representing a document's body	covid:1c3f83f83bc725064f9d634d10facb8ec2254bec#body_text
is schema:about of	named entity 'group' named entity 'pneumonia' named entity 'Efficacy' named entity 'disease' named entity 'progression' named entity 'met' named entity 'symptom' named entity 'risk factors' named entity 'progression' named entity 'body temperature' named entity 'risk factors' named entity 'group' named entity 'group' named entity 'respiratory' named entity 'progression' covid:arg/1c3f83f83bc725064f9d634d10facb8ec2254bec named entity 'stabilization' named entity 'higher' named entity 'admission' named entity 'progression' named entity 'maximum' named entity 'progression' named entity 'group' named entity 'group' named entity 'pneumonia' named entity '95% CI' named entity 'elevated' named entity 'samples' named entity 'patients' named entity 'coronavirus' named entity 'disease' named entity 'Categorical variables' named entity '95% CI' named entity 'risk factors' named entity 'body temperature' named entity 'COVID-19' named entity 'C-reactive protein' named entity 'respiratory support' named entity 'regression analysis' named entity 'Continuous variables' named entity 'C-reactive protein' named entity 'respiratory failure' named entity 'coronavirus disease' named entity 'lung' named entity 'pneumonia' named entity 'secretion' named entity 'mmHg' named entity 'CT scan' named entity 'Huanan Seafood Market' named entity 'Huanan Seafood Market' named entity 'antibiotic treatment' named entity 'significant difference' named entity 'viral infections' named entity 'fever' named entity 'COVID' named entity 'pneumonia' named entity 'risk factors' named entity 'Huanan Seafood Market' named entity 'coronavirus' named entity 'infection' named entity 'HIV' named entity 'SPSS' named entity 'Wuhan' named entity 'glucocorticoids' named entity 'D-dimer' named entity 'anti-bacterial' named entity 'anti-bacterial' named entity 'univariate analysis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software